- ResMed’s adjusted EPS for Q4 is $2.08, surpassing last year’s $1.60 and meeting the $2.07 estimate.
- Revenue hits $1.22 billion, showing a 9% year-over-year growth and meeting expectations.
- Global devices revenue is $635.1 million, a 5.4% increase from last year, though below the $643.2 million estimate.
- Global masks and other revenue totals $436.2 million, a significant 14% rise, beating the $419.6 million estimate.
- Global software as a service revenue reaches $151.9 million, up 9.6%, slightly above the $150.2 million estimate.
- Operating income stands at $381.2 million, a substantial 38% increase from last year, exceeding the $375.2 million estimate by analysts.
- Adjusted gross margin improves to 59.1% compared to last year’s 55.8%, and above the 58% estimate.
- ResMed receives 8 buy ratings and 6 hold ratings, with no sell ratings noted.
Resmed Inc on Smartkarma
Analysts on Smartkarma, like Baptista Research, have been closely following ResMed Inc., a company known for its innovative healthcare solutions. In their recent report titled “ResMed Inc.: What Are Their Latest Products & Their Expected Revenue Impact? – Major Drivers,” Baptista Research highlighted ResMed’s strong performance in the third financial quarter of 2024. The company demonstrated robust top-line growth and double-digit bottom-line growth, driven by the continued demand for their devices globally and significant growth in their Software as a Service business and masks and accessories segment. This growth is especially noteworthy considering the company’s exceptional growth in the previous year.
Furthermore, Baptista Research‘s insights on “ResMed Inc: Potential expansion of sleep awareness and population health management strategies to boost growth! – Major Drivers,” shed light on ResMed’s Q2 FY2024 earnings, showcasing strong overall execution with double-digit growth in both top and bottom lines. The report emphasized ResMed’s global growth in devices and Software as a Service business, positioning the company to address the widespread issue of sleep-related conditions affecting billions worldwide. Analysts like those at Baptista Research provide valuable perspectives on ResMed’s strategic initiatives and growth potential in the healthcare sector.
A look at Resmed Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking at ResMed Inc’s Smart Scores, the company seems to have a promising long-term outlook. With a strong focus on growth and momentum, scoring 4 on both factors, ResMed appears poised for expansion and continuous upward movement in the market. This indicates that the company is likely to see steady growth and increasing investor interest over time.
While the value and dividend scores are not as high at 2 each, ResMed’s resilience score of 3 suggests that the company has the ability to weather market fluctuations and economic challenges. With a core business centered around developing and selling medical equipment for sleep disordered breathing, ResMed Inc. is positioned to leverage its expertise and continue its global reach through subsidiaries and distributors in various countries.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
